Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract Overall Abstract: NMDAR antibodies have been described in association with some people with schizophrenia. However the finding is still controversial, and in particular some groups describe equal prevalence of antibodies in patients with schizophrenia as other disease controls, or in healthy control subjects. this symposium includes the leading academics undertaking research in this area and will discuss the hot topics in the area, reviewing the latest evidence from a range of perspectives. This will include comparison of testing methods for NMDAR antibodies, discussion of functional effects of NMDAR antibodies with relevance to schizophrenia, an update on prevalence studies of antibodies in psychosis and at risk mental states, and clinical data on the experience of screening patients for NMDAR antibodies in psychiatric hospitals. The discussant is Sarosh Irani, associate professor in neurology at the University of Oxford, who led the first European case series description of NMDAR antibodies.

Type

Journal article

Journal

Schizophrenia bulletin

Publication Date

04/2018

Volume

44

Pages

S60 - S60

Addresses

University of Oxford